NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA

EATON CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

SATURDAY MAY 3RD, 2014: 11:00 AM – 3:45 PM

CHAIR: K. CHI & N. FLESHNER

(03:45 PM – 04:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

– To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
– To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
– To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
– To provide mentoring opportunities for investigators new to clinical trial research.
– To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

11:00 am WELCOME K. Chi/N. Fleshner

11:05 am TRIALS WITHOUT ISSUES K. Chi/N. Fleshner

OPEN TRIALS
PR.15 Pilot Study of HDR Brachytherapy in Intermediate Risk CaP (E. Vigneault/ A. Loblaw)
BL.12 A Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma (K. Sridhar)
PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only (F. Saad/M. Gleave)

CLOSED, PENDING ANALYSES/REPORTING
BL.8/EORTC 30994 (F. Saad/L. Wood)
REC.2/ECOG E2805 Sunitinib/placebo vs. Sorafenib/placebo vs. placebo in resected RCC (M. Jewett/ L. Wood)

continued on next page …
11:15 am **OPEN TRIALS WITH ISSUES**
IND.209: Reolysin in combination with docetaxel and prednisone or docetaxel and prednisone alone in metastatic CRPC
B. Eigl
PR.13 (RADICALS)/MRC PR.10
C. Catton
BLC.1 A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer
W. Kassouf

11:30 am **CLOSED TRIALS WITH RESULTS**
IND.205: PX-866 in recurrent or metastatic CRPC
S. Hotte
PR.C.2/CALGB 90202 Early vs. Standard Zoledronic Acid in CaP metastatic to bone
K. Chi

**UPDATE ON NCIC CTG/INTERGROUP APPROVED STUDIES**
11:35 am PR.C.4 (Alliance - phase III Enzalutamide + Abiraterone in castration resistant metastatic prostate cancer)
K. Chi
11:40 am PR.17 (ANZUP - ENZAMET - phase III testosterone suppression with or without Enzalutamide as first line metastatic prostate cancer)
S. North

11:45 am **CUOG STUDIES**
Affinity (F. Saad)
Synergy (K. Chi)
AVIAS (L. Klotz)
EORTC/Cytoreductive (M. Jewett)
Hypothermia RCC (I. Cagiannos)
Propsect (F. Saad)
ProstVac (F. Saad)

12:00 pm **LUNCH**

1:30 pm **Plenary Presentation:** Enzalutamide in earlier prostate cancer stages and strategy to define robust intermediate clinical endpoints for overall survival.
Dr. Sweeney's biography.pdf

2:10 pm **DOG REPORTS/NEW PROPOSALS/GU DIRECTIONS**
Localized Prostate Cancer
Advanced Prostate Cancer
Bladder
Kidney
Testes
Correlative Studies
A. Loblaw/N. Fleshner
K. Chi
S. North/W. Kassouf/A. So
A. Kapoor/J. Knox
P. Chung
R. Bristow

3:45 pm **Meeting Adjourned**

3:45 PM – 4:15 PM **EXECUTIVE COMMITTEE MEETING – CLOSED**